Small Caps Today

Magazine variation 3

Nov 27, 2025

Sickle-Cell Setback Or Acquisition Setup? Agios’ 48% Drop Could Draw Dealmakers

Agios plunged 48% after its Phase III Pyrukynd trial delivered mixed results, missing key pain-crisis and fatigue endpoints. Despite strong hemoglobin gains, AGIO still seeks FDA approval.

7' read
Stock Market Today: Wall Street Extends Winning Streak as Dow, S&P 500, Nasdaq Rally into Thanksgiving
Market MoversNews

Stock Market Today: Wall Street Extends Winning Streak as Dow, S&P 500, Nasdaq Rally into Thanksgiving

·Nov 26, 2025
Priority Technology Turmoil: Shareholder Revolt Explodes Over CEO’s Low-Ball Takeover Bid
CompanyDeep DiveMarket MoversTech

Priority Technology Turmoil: Shareholder Revolt Explodes Over CEO’s Low-Ball Takeover Bid

·Nov 26, 2025
Sprout Social Jumps on M&A Chatter — What the Adobe Rumors Really Mean!
CompanyDeep DiveMarket MoversNews

Sprout Social Jumps on M&A Chatter — What the Adobe Rumors Really Mean!

·Nov 26, 2025
Retail Sales Cool as Inflation Jitters and Shutdown Delays Cloud Consumer Outlook
FinanceNews

Retail Sales Cool as Inflation Jitters and Shutdown Delays Cloud Consumer Outlook

·Nov 25, 2025